Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors von Piha-Paul, Sarina A, Hann, Christine L, French, Christopher A, Cousin, Sophie, Braña, Irene, Cassier, Phillippe A, Moreno, Victor, de Bono, Johann S, Harward, Sara Duckworth, Ferron-Brady, Geraldine, Barbash, Olena, Wyce, Anastasia, Wu, Yuehui, Horner, Thierry, Annan, Meg, Parr, Nigel J, Prinjha, Rabinder K, Carpenter, Christopher L, Hilton, John, Hong, David S, Haas, Naomi B, Markowski, Mark C, Dhar, Arindam, O'Dwyer, Peter J, Shapiro, Geoffrey I

Volltext

Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia von Stein, Eytan M, DeAngelo, Daniel J, Chromik, Jörg, Chatterjee, Manik, Bauer, Sebastian, Lin, Chia-Chi, Suarez, Cristina, De Vos, Filip, Steeghs, Neeltje, Cassier, Phillippe A, Tai, David, Kiladjian, Jean-Jacques, Yamamoto, Noboru, Mous, Rogier, Esteve, Jordi, Minami, Hironobu, Ferretti, Stéphane, Guerreiro, Nelson, Meille, Christophe, Radhakrishnan, Rajkumar, Pereira, Bernard, Mariconti, Luisa, Halilovic, Ensar, Fabre, Claire, Carpio, Cecilia

Volltext

Abstract CT326: Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors von Sequist, Lecia V., Cassier, Phillippe, Varga, Andrea, Tabernero, Josep, Schellens, Jan H., Delord, Jean-Pierre, LoRusso, Patricia, Camidge, D. Ross, Medina, Manuel Hidalgo, Schuler, Martin, Campone, Mario, Tian, G. Gary, Wong, Steven, Corral, Jesus, Isaacs, Randi, Sen, Suman K., Porta, Diana Graus, Kulkarni, Swarupa G., Lefebvre, Caroline, Wolf, Jürgen

Volltext